In This Issue - December 2012
Post–Liver Transplant Outcomes, Treatments
New studies take aim at improving hepatitis C virus infection post-transplant outcomes; reducing post-transplant, tacrolimus-associated renal dysfunction; determining the value of young donor age; and finding factors associated with acetaminophen-associated acute liver failure.
Pay Rule Contains Good and Bad News
Medicare’s physician fee schedule for 2013 contains both a 26.5% pay cut based on the Sustainable Growth Rate formula and pay increases for care coordination and for primary care provided under Medicaid.
Fatty Liver Cited for Hepatocellular Carcinoma Increase
Nonalcoholic fatty liver disease without cirrhosis appears to be a significant contributor to the rise in the incidence of hepatocellular carcinoma in the past two decades, according to a study linking population-based data from the National Cancer Institute with Medicare enrollment and claim files during 1993-2007.
Dabigatran, Warfarin Bleed Risk Equal
The Food and Drug Administration is satisfied that dabigatran’s bleeding risk is no greater than that of warfarin and will not change the drug’s label.
Panel Calls for More Safety Data for Hepatitis B Vaccine
Despite evidence of effectiveness and enthusiasm about its potential, more safety data in thousands of people are needed before a two-dose hepatitis B vaccine can be approved for use in adults, according to the majority of a Food and Drug Administration advisory panel.
Download PDF Or Interactive Version
No comments:
Post a Comment